NYSE:HIMS Hims & Hers Health (HIMS) Stock Price, News & Analysis → This company has increased its dividend every year for 54 years (From DTI) (Ad) Free HIMS Stock Alerts $12.38 -0.31 (-2.44%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$12.35▼$12.8850-Day Range$9.40▼$16.7252-Week Range$5.65▼$17.16Volume3.89 million shsAverage Volume4.71 million shsMarket Capitalization$2.65 billionP/E RatioN/ADividend YieldN/APrice Target$14.85 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Hims & Hers Health alerts: Email Address Hims & Hers Health MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.62 Rating ScoreUpside/Downside19.9% Upside$14.85 Price TargetShort InterestBearish9.36% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 15 Articles This WeekInsider TradingSelling Shares$8.49 M Sold Last QuarterProj. Earnings Growth130.00%From $0.10 to $0.23 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.29 out of 5 starsMedical Sector297th out of 914 stocksOffices & Clinics Of Medical Doctors Industry1st out of 7 stocks 3.3 Analyst's Opinion Consensus RatingHims & Hers Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 8 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageHims & Hers Health has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.36% of the float of Hims & Hers Health has been sold short.Short Interest Ratio / Days to CoverHims & Hers Health has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hims & Hers Health has recently increased by 1.72%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHims & Hers Health does not currently pay a dividend.Dividend GrowthHims & Hers Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HIMS. Previous Next 2.4 News and Social Media Coverage News SentimentHims & Hers Health has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Hims & Hers Health this week, compared to 6 articles on an average week.Search InterestOnly 44 people have searched for HIMS on MarketBeat in the last 30 days. This is a decrease of -28% compared to the previous 30 days.MarketBeat Follows37 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 95% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,487,124.00 in company stock.Percentage Held by Insiders31.63% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Hims & Hers Health are expected to grow by 130.00% in the coming year, from $0.10 to $0.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hims & Hers Health is -112.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hims & Hers Health is -112.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHims & Hers Health has a P/B Ratio of 7.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Hims & Hers Health Stock (NYSE:HIMS)Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.Read More HIMS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HIMS Stock News HeadlinesApril 9, 2024 | insidertrades.comMelissa Baird Sells 11,751 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) StockApril 9, 2024 | insidertrades.comHims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 188,888 SharesApril 17, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.April 3, 2024 | insidertrades.comInsider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 2,503 Shares of StockMarch 26, 2024 | marketbeat.com3 Stocks With Unusual Call Option ActivityWhen traders stampede into call options, it typically means they expect an event to come, pushing the underlying stock higher soon. Because options expire at a given date, these traders must get their thesis right before expiration or risk losing their entire investment.March 26, 2024 | marketbeat.com3 Stocks With Unusual Call Option Activity (HIMS)Three stocks reported rising call option buying activity could see even higher prices soon. Analysts see the writing on the wall, and traders stampeded inMarch 22, 2024 | insidertrades.comOluyemi Okupe Sells 9,912 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) StockMarch 20, 2024 | insidertrades.comInsider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Director Sells 10,044 Shares of StockApril 17, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 19, 2024 | marketbeat.comLifeMD Shares Come Back to Life on GLP-1 Business Growth (HIMS)LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024March 17, 2024 | insidertrades.comIrene Becklund Sells 2,747 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) StockApril 17, 2024 | investorplace.comThe Disruptor's Portfolio: 3 Stocks Shaping the New EconomyApril 17, 2024 | msn.comJefferies Downgrades Hims & Hers Health (HIMS)April 17, 2024 | americanbankingnews.comHims & Hers Health (NYSE:HIMS) Given Hold Rating at Jefferies Financial GroupApril 16, 2024 | finance.yahoo.comJefferies downgrades Hims & Hers Health on growth concernsApril 16, 2024 | benzinga.comUnpacking the Latest Options Trading Trends in Hims & Hers HealthApril 16, 2024 | msn.comHims & Hers slips as Jefferies cuts on valuationApril 15, 2024 | businesswire.comHims & Hers to Announce First Quarter 2024 Financial Results on May 6, 2024April 12, 2024 | americanbankingnews.comHims & Hers Health (NYSE:HIMS) Coverage Initiated by Analysts at Canaccord Genuity GroupApril 11, 2024 | americanbankingnews.comHims & Hers Health (NYSE:HIMS) Earns Buy Rating from Analysts at Canaccord Genuity GroupApril 11, 2024 | markets.businessinsider.comHims & Hers Health Outperforms: Strong Sales Growth and Brand Value Reinforce Buy RatingApril 10, 2024 | investing.comHims & Hers Health CEO sells over $4.9 million in company stockApril 10, 2024 | benzinga.comBreaking Down Hims & Hers Health: 6 Analysts Share Their ViewsApril 10, 2024 | americanbankingnews.comHims & Hers Health, Inc. (NYSE:HIMS) Receives Average Rating of "Moderate Buy" from AnalystsApril 9, 2024 | americanbankingnews.comHims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird Sells 11,751 SharesApril 8, 2024 | finance.yahoo.comHims & Hers Health, Inc. (NYSE:HIMS) Is About To Turn The CornerApril 6, 2024 | msn.comGot $2,000? 2 Unbelievable Growth Stocks Up 58% and 30% to Buy in the New Bull MarketSee More Headlines Receive HIMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today4/17/2024Next Earnings (Confirmed)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Offices & clinics of medical doctors Sub-IndustryN/A Current SymbolNYSE:HIMS CUSIPN/A CIK1773751 Webwww.forhims.com Phone415-851-0195FaxN/AEmployees1,046Year FoundedN/APrice Target and Rating Average Stock Price Target$14.85 High Stock Price Target$20.00 Low Stock Price Target$10.00 Potential Upside/Downside+19.9%Consensus RatingModerate Buy Rating Score (0-4)2.62 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($0.11) Trailing P/E RatioN/A Forward P/E Ratio123.80 P/E GrowthN/ANet Income$-23,550,000.00 Net Margins-2.70% Pretax Margin-2.47% Return on Equity-7.21% Return on Assets-5.81% Debt Debt-to-Equity RatioN/A Current Ratio3.00 Quick Ratio2.74 Sales & Book Value Annual Sales$872 million Price / Sales3.04 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book7.69Miscellaneous Outstanding Shares214,250,000Free Float146,483,000Market Cap$2.65 billion OptionableOptionable Beta0.91 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Andrew Dudum (Age 35)Co-Founder, Chairman & CEO Comp: $1.7MMr. Yemi Okupe (Age 38)Chief Financial Officer Comp: $804.05kMs. Melissa Baird (Age 46)Chief Operating Officer Comp: $917.67kMs. Irene A. Becklund (Age 39)Senior VP, Controller & Principal Accounting Officer Comp: $361.12kMs. Soleil Teubner Boughton (Age 45)Chief Legal Officer & Corporate Secretary Comp: $782.66kMr. Mike Chi (Age 43)Chief Marketing Officer Comp: $514.77kDr. Patrick Carroll M.D. (Age 66)Chief Medical Officer, Member of Medical Advisory Board & Director Comp: $27.03kMs. Khobi BrooklynChief Communications OfficerMs. Amee ParekhSenior Vice President of Human ResourcesDr. Peter Stahl M.D.Senior VP & Member of Medical Advisory BoardMore ExecutivesKey CompetitorsTeladoc HealthNYSE:TDOCMorphoSysNASDAQ:MORCertaraNASDAQ:CERTQuidelOrthoNASDAQ:QDELIndiviorNASDAQ:INDVView All CompetitorsInsiders & InstitutionsSoleil BoughtonSold 2,503 sharesTotal: $34,916.85 ($13.95/share)Counterpoint Mutual Funds LLCBought 18,397 shares on 4/15/2024Ownership: 0.009%Fragasso Group Inc.Bought 15,685 shares on 4/10/2024Ownership: 0.007%Melissa BairdSold 11,751 sharesTotal: $173,209.74 ($14.74/share)Melissa BairdSold 11,751 sharesTotal: $171,329.58 ($14.58/share)View All Insider TransactionsView All Institutional Transactions HIMS Stock Analysis - Frequently Asked Questions Should I buy or sell Hims & Hers Health stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last twelve months. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HIMS shares. View HIMS analyst ratings or view top-rated stocks. What is Hims & Hers Health's stock price target for 2024? 13 Wall Street research analysts have issued 12 month target prices for Hims & Hers Health's shares. Their HIMS share price targets range from $10.00 to $20.00. On average, they predict the company's share price to reach $14.85 in the next year. This suggests a possible upside of 19.9% from the stock's current price. View analysts price targets for HIMS or view top-rated stocks among Wall Street analysts. How have HIMS shares performed in 2024? Hims & Hers Health's stock was trading at $8.90 on January 1st, 2024. Since then, HIMS stock has increased by 39.1% and is now trading at $12.38. View the best growth stocks for 2024 here. Are investors shorting Hims & Hers Health? Hims & Hers Health saw a decline in short interest in February. As of February 29th, there was short interest totaling 12,650,000 shares, a decline of 6.1% from the February 14th total of 13,470,000 shares. Based on an average trading volume of 4,040,000 shares, the short-interest ratio is currently 3.1 days. Currently, 9.1% of the company's shares are sold short. View Hims & Hers Health's Short Interest. When is Hims & Hers Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our HIMS earnings forecast. How can I listen to Hims & Hers Health's earnings call? Hims & Hers Health will be holding an earnings conference call on Monday, May 6th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were Hims & Hers Health's earnings last quarter? Hims & Hers Health, Inc. (NYSE:HIMS) announced its quarterly earnings results on Monday, February, 26th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.03. The company earned $246.60 million during the quarter, compared to the consensus estimate of $245.84 million. Hims & Hers Health had a negative trailing twelve-month return on equity of 7.21% and a negative net margin of 2.70%. The company's revenue was up 47.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.05) EPS. What ETFs hold Hims & Hers Health's stock? ETFs with the largest weight of Hims & Hers Health (NYSE:HIMS) stock in their portfolio include Amplify Online Retail ETF (IBUY), SPDR S&P Health Care Services ETF (XHS), Global X Telemedicine & Digital Health ETF (EDOC), iShares Virtual Work and Life Multisector ETF (IWFH), Fidelity Digital Health ETF (FDHT), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and Global X Millennial Consumer ETF (MILN). What guidance has Hims & Hers Health issued on next quarter's earnings? Hims & Hers Health updated its first quarter 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $267.0 million-$272.0 million, compared to the consensus revenue estimate of $251.3 million. Who are Hims & Hers Health's major shareholders? Hims & Hers Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.01%), Counterpoint Mutual Funds LLC (0.01%) and Fragasso Group Inc. (0.01%). Insiders that own company stock include Alex Bard, Andrew Dudum, David B Wells, David B Wells, Irene Becklund, Jack Abraham, Jules A Maltz, Lynne Chou O'keefe, Melissa Baird, Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee. View institutional ownership trends. How do I buy shares of Hims & Hers Health? Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:HIMS) was last updated on 4/17/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsYou won't believe what Citigroup just did to it's depositorsAmerican AlternativeAI healthcare stock poised for 36,996% growth?Behind the MarketsBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hims & Hers Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.